Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Depreciation & Amortization (CF) (2016 - 2025)

IGC Pharma (IGC) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $119000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization (CF) fell 17.93% to $119000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $571000.0 through Sep 2025, down 9.51% year-over-year, with the annual reading at $618000.0 for FY2025, 2.98% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $119000.0 at IGC Pharma, down from $141000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $172000.0 in Q4 2022, with the low at $119000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $157315.8, with a median of $160000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) surged 121.33% in 2021, then dropped 17.93% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $166000.0 in 2021, then grew by 3.61% to $172000.0 in 2022, then decreased by 6.98% to $160000.0 in 2023, then fell by 1.88% to $157000.0 in 2024, then decreased by 24.2% to $119000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $119000.0, $141000.0, and $154000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.